https://avalynmed.com/publications/long-term-safety-data-of-inhaled-pirfenidone-ap01-in-idiopathic-pulmonary-fibrosis-ipf-and-non-ipf-interstitial-lung-disease-ild-patients/ 2024-11-08T21:19:31+00:00 https://avalynmed.com/publications/improvement-in-hrct-lung-fibrosis-with-inhaled-pirfenidone-is-associated-with-better-health-related-quality-of-life-scores-in-patients-with-idiopathic-pulmonary-fibrosis-2/ 2024-11-08T21:19:45+00:00 https://avalynmed.com/publications/inhaled-pirfenidone-ap01-forced-vital-capacity-fvc-data-from-the-atlas-study-vs-placebo-from-3-historical-idiopathic-pulmonary-fibrosis-ipf-randomised-controlled-trials-rcts/ 2024-11-08T21:20:21+00:00 https://avalynmed.com/publications/nebulised-pirfenidone-in-non-idiopathic-pulmonary-fibrosis-ipf-progressive-pulmonary-fibrosis-ppf-first-look-at-fvc-data/ 2024-11-08T21:20:58+00:00 https://avalynmed.com/publications/inhalation-improves-pirfenidone-animal-efficacy-through-superior-pulmonary-and-vascular-pharmacokinetics/ 2024-11-08T21:27:00+00:00 https://avalynmed.com/publications/inhaled-nintedanib-predictive-sheep-model-for-human-dose-selection-and-tolerability/ 2024-11-08T21:32:41+00:00 https://avalynmed.com/publications/nebulised-pirfenidone-in-idiopathic-pulmonary-fibrosis-ipf-first-look-at-fvc-data/ 2024-11-08T21:32:59+00:00 https://avalynmed.com/publications/pharmacokinetics-and-safety-of-pirfenidone-following-inhaled-delivery-to-sheep-a-viable-approach-to-treating-idiopathic-pulmonary-fibrosis/ 2025-10-08T13:49:17+00:00 https://avalynmed.com/publications/improvement-in-hrct-lung-fibrosis-with-inhaled-pirfenidone-is-associated-with-better-health-related-quality-of-life-scores-in-patients-with-idiopathic-pulmonary-fibrosis/ 2025-10-08T13:53:14+00:00 https://avalynmed.com/publications/ats2023-poster-long-term-data-from-ipf-and-ppf-participants-in-ap01-005/ 2025-10-08T13:56:03+00:00 https://avalynmed.com/publications/inhaled-pirfenidone-reduces-the-risk-of-disease-progression-a-post-hoc-analysis-of-the-atlas-study/ 2025-10-08T13:57:55+00:00 https://avalynmed.com/publications/differences-in-e-lung-biomarker-scores-between-treatment-groups-in-post-hoc-analysis-of-the-atlas-inhaled-pirfenidone-solution-ap01-for-ipf-clinical-trial/ 2025-10-08T13:58:24+00:00 https://avalynmed.com/publications/safety-and-efficacy-of-inhaled-pirfenidone-ap01-in-the-atlas-open-label-extension-study/ 2025-10-08T13:58:51+00:00 https://avalynmed.com/publications/inhalation-innovation-phase-2b-study-design-on-inhaled-pirfenidone-in-the-treatment-of-progressive-pulmonary-fibrosis/ 2025-10-08T14:54:25+00:00 https://avalynmed.com/publications/cough-adverse-events-and-fvc-decline-in-the-atlas-study-of-inhaled-pirfenidone-ap01-in-idiopathic-pulmonary-fibrosis/ 2025-10-08T14:54:42+00:00 https://avalynmed.com/publications/correlation-of-early-cough-with-disease-activity-measured-by-high-resolution-ct-in-atlas-a-phase-1b-study-of-inhaled-pirfenidone-in-idiopathic-pulmonary-fibrosis/ 2025-10-08T14:54:54+00:00 https://avalynmed.com/publications/monte-carlo-external-control-arm-generation-utilizing-real-world-patient-data-and-deep-learning-based-quantitative-ct-metrics-demonstrates-treatment-effect-in-the-atlas-ipf-trial/ 2025-10-08T14:55:22+00:00 https://avalynmed.com/publications/long-term-safety-and-efficacy-data-with-inhaled-pirfenidone-ap01-in-the-atlas-open-label-extension-study-up-to-240-weeks/ 2025-10-08T14:55:55+00:00 https://avalynmed.com/publications/dose-dependent-change-of-inhaled-pirfenidone-seen-in-lung-volume-and-fibrosis-quantification-in-patients-with-ipf-a-deep-learning-image-based-analysis-of-data-from-the-atlas-phase-1b-trial/ 2025-10-08T14:56:12+00:00 https://avalynmed.com/publications/direct-lung-administration-of-nintedanib-reduces-lung-fibrosis-in-a-multi-challenge-bleomycin-rat-model/ 2025-10-08T14:59:36+00:00 https://avalynmed.com/publications/a-double-blind-placebo-controlled-randomized-phase-1-study-to-evaluate-safety-tolerability-and-pharmacokinetics-after-single-or-repeat-twice-daily-doses-of-ap02-a-nebulized-formulation-of-ninteda/ 2025-10-08T15:01:49+00:00 https://avalynmed.com/publications/inhaled-nintedanib-ap02-for-the-treatment-of-ipf-safety-tolerability-and-pharmacokinetics-after-single-ascending-doses-to-healthy-subjects-and-ipf-patients/ 2025-10-08T15:02:00+00:00 https://avalynmed.com/publications/inhalation-innovation-phase-2-study-design-of-inhaled-nintedanib-in-the-treatment-of-idiopathic-pulmonary-fibrosis/ 2025-10-08T15:02:21+00:00 https://avalynmed.com/publications/assessment-of-regional-lung-deposition-of-aerosol-aerodone-in-idiopathic-pulmonary-fibrosis-patients-using-functional-respiratory-imaging/ 2025-10-08T15:03:00+00:00 https://avalynmed.com/publications/design-of-the-mist-study-a-double-blind-randomised-placebo-controlled-phase-2b-trial-of-pirfenidone-solution-for-inhalation-in-patients-with-progressive-pulmonary-fibrosis/ 2026-01-07T01:49:24+00:00 https://avalynmed.com/publications/atlas-study-of-inhaled-pirfenidone-ap01-in-adults-with-ipf-published-thorax/ 2026-01-08T22:47:06+00:00 https://avalynmed.com/publications/a-randomized-double-blinded-placebo-controlled-dose-escalation-phase-1-study-of-aerosolized-pirfenidone/ 2026-01-08T22:48:18+00:00 https://avalynmed.com/publications/aerosol-pirfenidone-pharmacokinetics-after-inhaled-delivery-in-sheep-a-viable-approach-to-treating-idiopathic-pulmonary-fibrosis-2/ 2026-01-08T22:49:06+00:00 https://avalynmed.com/publications/fibroblast-matrix-interplay-nintedanib-and-pirfenidone-modulate-the-effect-of-ipf-fibroblast-conditioned-matrix-on-normal-fibroblast-phenotype-2/ 2026-01-08T22:51:41+00:00 https://avalynmed.com/publications/fibroblast-matrix-interplay-nintedanib-and-pirfenidone-modulate-the-effect-of-ipf-fibroblast-conditioned-matrix-on-normal-fibroblast-phenotype/ 2026-01-08T22:51:48+00:00 https://avalynmed.com/publications/inhalation-innovation-an-overview-of-ap02-003-a-new-trial-studying-inhaled-nintedanib-in-the-treatment-of-idiopathic-pulmonary-fibrosis/ 2026-01-08T22:53:43+00:00 https://avalynmed.com/publications/hypoxia-inducible-factor-1a-supports-a-pro-fibrotic-phenotype-loop-in-idiopathic-pulmonary-fibrosis/ 2026-01-08T22:55:06+00:00 https://avalynmed.com/publications/inhalation-a-means-to-explore-and-optimize-nintedanibs-pharmacokinetic-pharmacodynamic-relationship/ 2026-01-08T22:56:59+00:00 https://avalynmed.com/publications/inhaled-nintedanib-is-well-tolerated-and-delivers-key-pharmacokinetic-parameters-required-to-treat-bleomycin-induced-pulmonary-fibrosisinhaled-nintedanib-is-well-tolerated-and-delivers-key-pharmacokin/ 2026-01-08T22:57:35+00:00 https://avalynmed.com/publications/inhalation-a-means-to-improve-existing-ipf-therapies/ 2026-01-08T23:01:06+00:00 https://avalynmed.com/publications/living-with-idiopathic-pulmonary-fibrosis-ipf-unpacking-the-shared-realities-of-daily-life-emotional-burden-and-finding-the-way/ 2026-01-08T23:01:49+00:00 https://avalynmed.com/publications/navigating-the-ipf-maze-a-mixed-methods-patient-experience-study-to-understand-the-diagnostic-journey-of-ipf/ 2026-01-08T23:01:55+00:00 https://avalynmed.com/publications/improved-quality-of-life-reduced-quantitative-lung-fibrosis-in-a-trial-of-inhaled-pirfenidone-for-idiopathic-pulmonary-fibrosis/ 2026-03-25T11:56:04+00:00 https://avalynmed.com/publications/association-between-functional-improvement-and-structural-changes-in-quantitative-high-resolution-ct-in-atlas-a-phase-1b-study-of-inhaled-pirfenidone-in-idiopathic-pulmonary-fibrosis/ 2026-05-15T20:49:29+00:00 https://avalynmed.com/publications/the-gold-standard-of-care-what-patients-living-with-idiopathic-pulmonary-fibrosis-define-as-a-truly-supportive-and-empowering-healthcare-experience/ 2026-05-18T11:54:11+00:00 https://avalynmed.com/publications/systematic-approach-in-developing-a-user-centric-nebulizer-for-the-treatment-of-patients-living-with-pulmonary-fibrosis-the-first-formative-ap01-eflow-nebulizer-system-usability-study/ 2026-05-18T13:48:01+00:00 https://avalynmed.com/publications/nebulized-pirfenidone-ap01-for-progressive-pulmonary-fibrosis-in-connective-tissue-disease-associated-and-other-interstitial-lung-diseases-4-year-data-from-the-atlas-open-label-extension-trial/ 2026-06-02T23:00:11+00:00 https://avalynmed.com/publications/every-perspective-shapes-progress-patient-viewpoints-on-ipf-clinical-studies/ 2026-09-07T10:26:59+00:00 https://avalynmed.com/publications/in-silico-modeling-of-a-novel-nebulized-pirfenidone-formulation-ap01-predicts-aerosol-distribution-throughout-the-lung/ 2026-09-07T10:27:11+00:00 https://avalynmed.com/publications/nebulized-nintedanib-ap02-for-idiopathic-pulmonary-fibrosis-demonstrates-favorable-safety-and-lung-lining-fluid-exposures-results-from-two-phase-i-safety-tolerability-and-pharmacokinetics-studies/ 2026-09-22T12:09:02+00:00 https://avalynmed.com/publications/video-content-ebenbuild-in-silico-modeling-of-ap01-distribution/ 2026-09-25T19:56:25+00:00